Kyverna Therapeutics, Inc. (KYTX) vs Orchestra BioMed Holdings, Inc. (OBIO)
A side-by-side comparison of Kyverna Therapeutics, Inc. and Orchestra BioMed Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KYTX
Kyverna Therapeutics, Inc.
$6.25HealthcareDelayed quote: Oct 6, 2026, 1:30 PM EDT
OBIO
Orchestra BioMed Holdings, Inc.
$5.90HealthcareDelayed quote: Oct 6, 2026, 1:29 PM EDT
Total return — KYTX vs OBIO
growth of $100 · dividends reinvested · last 3yKYTX -78.9% (-40.5%/yr)OBIO -13.2% (-4.6%/yr)OBIO compounded faster over this window
KYTX OBIO
KYTX vs OBIO: by the numbers
- •KYTX is the larger company ($380M vs $353M market cap).
- •Both run net losses; KYTX's is the smaller (0.00% vs -184.60% net margin).
Metrics side by side
Valuation
| Metric | KYTX | OBIO |
|---|---|---|
| P/S ratio | N/A | 11.04 |
| P/B ratio | 2.29 | 18.27 |
Profitability
| Metric | KYTX | OBIO |
|---|---|---|
| Gross margin | 0.00% | 99.32% |
| Operating margin | 0.00% | -154.73% |
| Net margin | 0.00% | -184.60% |
| ROE | -92.20% | -200.64% |
| ROIC | -80.67% | -56.73% |
Growth (annualized)
| Metric | KYTX | OBIO |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 148.45% |
| Total return CAGR (5Y) | N/A | -9.35% |
Go deeper
Dig into the metrics
Kyverna Therapeutics ROEOrchestra BioMed ROEKyverna Therapeutics operating marginOrchestra BioMed operating marginKyverna Therapeutics revenue growthOrchestra BioMed revenue growthKyverna Therapeutics free cash flowOrchestra BioMed free cash flow
Kyverna Therapeutics & Orchestra BioMed appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.